Tiamat Sciences secured a $3 million seed financing round led by True Ventures.

Tiamat Sciences, a Belgian biotech startup that relocated to USA, announced that it completed a $3 million seed funding round.

The money was raised from American investors led by True Ventures, with participation from Social Impact Capital and Cantos.

Tiamat Sciences, founded in 2019 by Clément Carlier and CEO France-Emmanuelle Adil, is a manufacturer of affordable animal-free growth factors and biomolecules using plants as bioreactors. The company has a proprietary plant molecular farming approach that combines biotechnology, vertical farming and computation design to reinvent recombinant proteins and manufacturing a wide range of high-value proteins from antigens to growth factors.

Tiamat was launched and operated from Belgium and relocated in the US, in the first part of 2021, as it is building a pilot production facility in Durham, North Carolina.